angiotensin ii has been researched along with Chronic Hepatitis C in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Angus, PW; Burrell, LM; Casley, D; Crowley, P; Grace, J; Herath, CB; Jia, Z; Lubel, JS; Sievert, W; Spencer, K; Tchongue, J | 1 |
| Bataller, R; Colmenero, J; De Minicis, S; Gwak, GY; Kluwe, J; Mencin, A; Osterreicher, CH; Pradere, JP; Schwabe, RF | 1 |
2 other study(ies) available for angiotensin ii and Chronic Hepatitis C
| Article | Year |
|---|---|
Angiotensin-(1-7), an alternative metabolite of the renin-angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-duct-ligated rat.
Topics: Actins; Adult; Angiotensin I; Angiotensin II; Animals; Bile Ducts; Cells, Cultured; Drug Evaluation, Preclinical; Female; Hepatitis C, Chronic; Humans; Hydroxyproline; Liver; Liver Cirrhosis; Liver Cirrhosis, Experimental; Male; Middle Aged; Peptide Fragments; Proto-Oncogene Mas; Proto-Oncogene Proteins; Rats; Rats, Sprague-Dawley; Receptors, G-Protein-Coupled; Renin; Renin-Angiotensin System; RNA, Messenger; Up-Regulation | 2009 |
Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition.
Topics: Angiotensin II; Animals; Anthracenes; Carrier Proteins; Cell Division; Cells, Cultured; Disease Models, Animal; Fatty Liver; Fibroblasts; Hepatic Stellate Cells; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Mutant Strains; Mitogen-Activated Protein Kinase 9; Phosphorylation; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Transforming Growth Factor beta | 2010 |